Meeder Asset Management Inc. Purchases 23,943 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Meeder Asset Management Inc. boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 32,355.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,017 shares of the biopharmaceutical company's stock after acquiring an additional 23,943 shares during the quarter. Meeder Asset Management Inc.'s holdings in TG Therapeutics were worth $947,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in TG Therapeutics by 16.2% in the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after acquiring an additional 290 shares during the period. Golden State Wealth Management LLC boosted its stake in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the period. Summit Investment Advisors Inc. grew its holdings in TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares in the last quarter. Xponance Inc. increased its position in TG Therapeutics by 5.3% during the 1st quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock worth $428,000 after buying an additional 543 shares during the period. Finally, Choreo LLC lifted its holdings in shares of TG Therapeutics by 7.6% during the first quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock worth $337,000 after buying an additional 602 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Price Performance

TGTX traded down $0.77 on Thursday, reaching $35.50. The stock had a trading volume of 1,811,501 shares, compared to its average volume of 1,456,212. The firm has a 50-day moving average of $36.79 and a 200-day moving average of $35.92. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of 147.92 and a beta of 1.91. TG Therapeutics, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. TG Therapeutics's quarterly revenue was up 90.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.07) EPS. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Activity

In other news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director owned 228,816 shares of the company's stock, valued at $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $43.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.